This funding call under Horizon Europe aims to accelerate the development of innovative biotechnology-based therapies by supporting the initial phases of clinical research. The call targets collaborative, multidisciplinary consortia involving SMEs, academia, clinicians, and research organizations to facilitate the transition from preclinical to clinical development of novel biotechnology-derived therapies. Eligible projects must include clinical studies (phase I, II, or I/II) and demonstrate significant economic potential and clear exploitation plans, including routes to commercialization. Proposals should address unmet medical needs and involve patient populations that would benefit most. The call encourages collaboration with European research infrastructures and emphasizes the competitiveness of the EU health biotech sector.

Opening: 22-05-2025
Deadline(s): 18-09-2025

Data provided by Kooperationsstelle Wissenschaft

This funding opportunity represents a pre-agreed draft that has not yet been officially approved by the European Commission. The final, approved version is expected to be published in the first quarter of 2025. This draft is provided for informational purposes and may be used to preliminarily form consortia and develop project ideas, but it is offered without any guarantees or warranties.